Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproNPRRF 74 Days Sales Outstanding is 89.98 as of Jun. 2026, which is 19% below its 10-year median of 110.47. GuruFocus rates NPRRF with a GF Score™ of 74/100 and a GF Value™ of $10.26. The stock has 6 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Nipro ranks worse than 74.48% on this metric.
Nipro's average Accounts Receivable for the
three
months ended in Jun. 2026 was $1,037 Mil. Nipro's Revenue for the
three
months ended in Jun. 2026 was $1,051 Mil.
Hence, Nipro's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 89.98.
The historical rank and industry rank for Nipro's Days Sales Outstanding or its related term are showing as below:
NPRRF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 90.75 Med: 110.47 Max: 124.31
Current: 90.75
During the past 13 years, Nipro's highest Days Sales Outstanding was 124.31. The lowest was 90.75. And the median was 110.47.
NPRRF's Days Sales Outstanding is ranked worse than 74.48% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 65.38
vs NPRRF: 90.75
Nipro's Days Sales Outstanding
increased
from Jun. 2025 (87.98) to Jun. 2026 (89.98).
Nipro (OTCPK:NPRRF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Nipro Days Sales Outstanding Related Terms
Nipro Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Nipro's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPRRF vs ISRG, BDX, RMD: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Nipro's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Nipro's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (NPRRF) has a Days Sales Outstanding of 89.98 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nipro and its competitors. This is 19% below median its historical median of 110.47. Over the past decade, Nipro's Days Sales Outstanding has ranged from 90.75 to 124.31. According to the industry distribution chart, Nipro ranks #604 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 74.5%.
Is Nipro's Days Sales Outstanding too high?
Nipro's current Days Sales Outstanding of 89.98 is 19% below median its 10-year median of 110.47. Over the past 10 years, this metric has ranged from a low of 90.75 to a high of 124.31. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.38. Nipro's value of 89.98 is 37.6% above this industry median. Based on the distribution chart, Nipro ranks #604 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nipro has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Nipro's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #604 out of 811 companies for Days Sales Outstanding. This places Nipro in the lower half of its industry. The industry median Days Sales Outstanding is 65.38. Nipro's value of 89.98 is 37.6% above this benchmark. Historically, Nipro's own Days Sales Outstanding has ranged from 90.75 to 124.31 over the past decade. While the company's 10-year median is 110.47 vs. the industry median of 65.38, Nipro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.38, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nipro's current Days Sales Outstanding of 89.98 is 37.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Nipro and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current Days Sales Outstanding is 89.98, which is 19% below median its own 10-year median of 110.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Nipro (NPRRF) has a current Days Sales Outstanding of 89.98. The stock's GF Value™ is $10.26, compared to a current price of $9.96 — trading 2.9% below its estimated fair value. The current Days Sales Outstanding is 89.98, which is 19% below median its 10-year median of 110.47 and 37.6% above the Medical Devices & Instruments industry median of 65.38. Nipro's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Nipro (NPRRF), the current Days Sales Outstanding is 89.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (NPRRF) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be undervalued.
The current stock price of $9.96 is trading 2.9% below its estimated GF Value™ of $10.26.
Key valuation signals for NPRRF:
Days Sales Outstanding: 89.98 (19% below median its 10-year median of 110.47)
GF Value™: $10.26 vs. price of $9.96 (2.9% below fair value)
Industry Position: 37.6% above the Medical Devices & Instruments median (#604 of 811)
No single metric tells the full story. See the NPRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
74GF Score
Get the complete analysis for NPRRF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPRRF has been successfully added to your 
